メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
田中 伸之
泌尿器科学
ウェブサイト
https://k-ris.keio.ac.jp/html/100005795_ja.html
h-index
2016
被引用数
27
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2007
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(121)
類似のプロファイル
(10)
フィンガープリント
Nobuyuki Tanakaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Neoplasm
69%
Nephroureterectomy
55%
Recurrent Disease
50%
Clear Cell Renal Cell Carcinoma
39%
Prostatectomy
36%
Bladder Cancer
29%
Prostate Cancer
25%
Malignant Neoplasm
23%
Multivariate Analysis
23%
Kidney Metastasis
21%
Biochemical Recurrence
21%
Prostate Specific Antigen
20%
Survival Rate
19%
Cancer Specific Survival
19%
Tumor Recurrence
16%
Cisplatin
16%
Bladder
16%
Bacilli
15%
Targeted Therapy
15%
Non Muscle Invasive Bladder Cancer
14%
Overall Survival
14%
Adrenalectomy
14%
Neutrophil
14%
Lymphocyte
13%
Cystectomy
13%
Hazard Ratio
11%
Biopsy
11%
Prognostic Factor
11%
Microvessel
11%
Kidney Function
11%
Bladder Tumor
10%
Androgen Deprivation Therapy
10%
Neoadjuvant Chemotherapy
9%
Urothelial Cancer
9%
Biological Marker
9%
Vasculotropin
9%
Cohort Analysis
9%
Pembrolizumab
8%
Castration Resistant Prostate Cancer
8%
Robot-Assisted Prostatectomy
8%
Angiotensin II
8%
Cancer Cell
7%
Upper Urinary Tract
7%
Muscle Invasive Bladder Cancer
7%
3D Imaging
7%
Progression Free Survival
7%
High Risk Population
7%
Mesenchymal-Epithelial Transition
7%
Hormone Therapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
60%
Neoplasm
45%
Recurrent Disease
39%
Prostate Cancer
29%
Bladder Cancer
26%
Non Muscle Invasive Bladder Cancer
25%
Tumor Recurrence
25%
Prostate Specific Antigen
24%
Malignant Neoplasm
22%
Kidney Metastasis
21%
Chemotherapy
18%
Renal Cell Carcinoma
18%
Castration Resistant Prostate Cancer
17%
Survival Rate
17%
Bladder Tumor
16%
Cisplatin
15%
Androgen
14%
C Reactive Protein
14%
Biochemical Recurrence
14%
Overall Survival
13%
Bacilli
12%
Renin
11%
Cancer Specific Survival
8%
Angiotensin
8%
Angiotensin II
8%
Biological Marker
7%
Fibrinogen
7%
Cushing Syndrome
7%
Drug Resistance
7%
Vasculotropin
7%
Tumor Growth
7%
Recurrence Free Survival
6%
Gleason Score
6%
Recurrence Risk
6%
Renin-Angiotensin System Inhibitor
6%
Receptor
6%
Disease
5%
Dipeptidyl Carboxypeptidase Inhibitor
5%
Cancer Staging
5%
Keyphrases
Upper Tract Urothelial Carcinoma
29%
Nephroureterectomy
24%
Radical Prostatectomy
20%
Biochemical Recurrence
15%
Cancer-specific Survival
11%
Non-muscle Invasive Bladder Cancer (NMIBC)
11%
Castration-resistant Prostate Cancer
10%
Metastatic Renal Cell Carcinoma (mRCC)
9%
Tumor Recurrence
8%
Bladder Cancer
8%
Multi-institution
7%
Prostate Cancer
7%
Muscle-invasive Bladder Cancer
7%
Vasohibin-1
7%
Renin-angiotensin System Blockade
7%
Adrenalectomy
7%
Bacillus
7%
Cancer Patients
7%
Multivariate Analysis
7%
Androgen Deprivation Therapy
6%
Prostate-specific Antigen
6%
Platinum Resistance
5%
Recurrent Disease
5%
Salvage Radiotherapy
5%
Independent Risk Factors
5%
